Revance Releases Third Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Revance Therapeutics (RVNC) Misses Q3 EPS by 8c
November 2, 2017 4:53 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.01), $0.08 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $50 thousand.
2017 Financial Outlook
Revance reaffirmed its financial guidance provided in January 2017. Revance expects cash... More
